News
-
Lee’s Pharmaceutical Holdings subsidiary Nova Pneuma has acquired inhaled drug delivery technology and other assets developed by Alexza Pharmaceuticals, the company said. Alexza merged with Grupo Ferrer in 2016. The deal, which is expected to close… Read more . . .
-
Savara has announced two new European patents covering Molbreevi molgramostim inhalation solution. The company said that it has received notification from the European Patent Office that it intends to grant a patent covering the liquid… Read more . . .
-
Milestone Pharmaceuticals announced that the FDA has approved Cardamyst etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT) and that the company expects to launch the product in early 2026. Milestone submitted the NDA… Read more . . .
-
CDMO Intertek announced that it has acquired a 29,000 sq ft facility in Melbourn, UK, which will allow the company to add to its GMP manufacturing capacity for inhaled drug products. The facility, which is… Read more . . .
-
Nebulizer maker HCMed, in partnership with several other OINDP-related organizations, has organized a new pitch day called RespireX that will debut in March 2026. Aimed at providing early stage start-ups or academic groups with support… Read more . . .
-
Amneal Pharmaceuticals announced that the FDA has approved the company’s ANDA for a generic version of Teva’s ProAir HFA albuterol MDI for the treatment of asthma. Amneal submitted the ANDA in 2023 and was sued… Read more . . .
-
US-based start-up CorriXR Therapeutics has announced a partnership with inhaled drug developer InhaTarget Therapeutics and device developer Merxin Ltd for development of an inhaled gene therapy for the treatment of lung cancer. InhaTarget will use its lipid… Read more . . .
-
Glenmark Pharmaceuticals has launched Nebzmart GFB Smartules (glycopyrronium / formoterol / budesonide) and Glenmark Airz FB Smartules (formoterol / budesonide) ampules for the treatment of COPD in India. According to the company, a clinical trial… Read more . . .
-
According to Blue Lake Biotechnology, the FDA has agreed to lift a partial clinical hold on a Phase 1/2a clinical trial of BLB201 intranasal RSV vaccine in children aged 8 months to 59 months with… Read more . . .
-
Nasus Pharma announced that it has initiated a Phase 2 study of the company’s NS002 epinephrine nasal powder, which the company is developing for the treatment of anaphylaxis. The open-label PK trial is expected to… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.